HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04153149 |
|
Recruitment Status :
Active, not recruiting
First Posted : November 6, 2019
Last Update Posted : February 13, 2024
|
Sponsor:
Alnylam Pharmaceuticals
Information provided by (Responsible Party):
Alnylam Pharmaceuticals
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This study will evaluate the efficacy and safety of vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) compared to placebo in patients with ATTR amyloidosis with cardiomyopathy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | Drug: Vutrisiran Drug: Sterile Normal Saline (0.9% NaCl) | Phase 3 |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 655 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) |
| Actual Study Start Date : | November 26, 2019 |
| Estimated Primary Completion Date : | February 2024 |
| Estimated Study Completion Date : | December 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Transthyretin amyloidosis
Drug Information
available for:
Votrisiran
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Vutrisiran 25 mg
Participants will receive vutrisiran 25 mg administered subcutaneously (SC) once every 3 months (q3M) during the double-blind period.
|
Drug: Vutrisiran
Vutrisiran 25 mg will be administered by SC injection q3M.
Other Name: ALN-TTRSC02 |
|
Placebo Comparator: Placebo
Participants will receive placebo during the double-blind period.
|
Drug: Sterile Normal Saline (0.9% NaCl)
Sterile normal saline (0.9% NaCl) will be administered by SC injection q3M. |
Primary Outcome Measures :
- Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) [ Time Frame: 30-36 months ]All-cause mortality and recurrent CV events (CV hospitalizations and urgent HF visits) will be compared between treatment groups using an Andersen-Gill model.
Secondary Outcome Measures :
- Change from Baseline in 6-Minute Walk Test (6-MWT) at Month 30 [ Time Frame: Baseline, Month 30 ]
- Change from Baseline in the Kansas City Cardiomyopathy Questionnaire Overall Summary (KCCQ-OS) at Month 30 [ Time Frame: Baseline, Month 30 ]The KCCQ is a 23-item self-administered questionnaire quantifying 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary [OS]). Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
- Change from Baseline in Mean Left Ventricular (LV) Wall Thickness by Echocardiographic Assessment at Month 30 [ Time Frame: Baseline, Month 30 ]
- Change from Baseline in Global Longitudinal Strain by Echocardiographic Assessment at Month 30 [ Time Frame: Baseline and Month 30 ]
- Composite Endpoint of All-Cause Mortality and Recurrent All-cause Hospitalizations and Urgent HF Visits [ Time Frame: 30-36 months ]All-cause mortality and recurrent all-cause hospitalizations and urgent HF visits will be compared between treatment groups using an Andersen-Gill model.
- All-cause Mortality [ Time Frame: 30-36 months ]
- Rate of Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) [ Time Frame: 30-36 months ]
- Change from Baseline in N-terminal prohormone B-type Natriuretic Peptide (NTproBNP) at Month 30 [ Time Frame: Baseline, Month 30 ]
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 85 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Has a documented diagnosis of transthyretin (ATTR) amyloidosis with cardiomyopathy, classified as either hereditary ATTR (hATTR) amyloidosis with cardiomyopathy or wild-type ATTR (wtATTR) amyloidosis with cardiomyopathy meeting pre-specified diagnostic criteria
- Has medical history of heart failure (HF) with at least 1 prior hospitalization for HF OR clinical evidence of HF
Exclusion Criteria:
- Has known primary amyloidosis or leptomeningeal amyloidosis
- Has New York Heart Association (NYHA) Class IV heart failure
- Has NYHA Class III heart failure AND is at high risk based on pre-specified criteria
- Has a polyneuropathy disability (PND) Score IIIa, IIIb, or IV at the Screening visit
- Has estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m^2
- Has received prior TTR-lowering treatment
- Has other non-TTR cardiomyopathy, hypertensive cardiomyopathy, cardiomyopathy due to valvular heart disease, or cardiomyopathy due to ischemic heart disease
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04153149
Locations
Show 79 study locations
Sponsors and Collaborators
Alnylam Pharmaceuticals
Investigators
| Study Director: | Medical Director | Alnylam Pharmaceuticals |
| Responsible Party: | Alnylam Pharmaceuticals |
| ClinicalTrials.gov Identifier: | NCT04153149 |
| Other Study ID Numbers: |
ALN-TTRSC02-003 2019-003153-28 ( EudraCT Number ) |
| First Posted: | November 6, 2019 Key Record Dates |
| Last Update Posted: | February 13, 2024 |
| Last Verified: | February 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Alnylam Pharmaceuticals:
|
ATTR Cardiomyopathy Amyloidosis TTR Transthyretin TTR-mediated amyloidosis Amyloidosis, Hereditary Amyloidosis, Hereditary, Transthyretin-Related Familial Amyloidosis |
RNAi therapeutic Transthyretin amyloid cardiomyopathy TTR cardiomyopathy ATTR-CM Wild-type TTR V122I TTR amyloidosis Amyloidosis, Wild Type |
Additional relevant MeSH terms:
|
Amyloid Neuropathies, Familial Cardiomyopathies Amyloidosis Heart Diseases Cardiovascular Diseases Proteostasis Deficiencies Metabolic Diseases Heredodegenerative Disorders, Nervous System |
Neurodegenerative Diseases Nervous System Diseases Amyloid Neuropathies Peripheral Nervous System Diseases Neuromuscular Diseases Genetic Diseases, Inborn Amyloidosis, Familial Metabolism, Inborn Errors |